Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Income from Continuing Operations for 6 consecutive years, with 5400000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 106.42% to 5400000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 17104000.0, a 35.64% decrease, with the full-year FY2024 number at 11136000.0, up 18.27% from a year prior.
  • Income from Continuing Operations was 5400000.0 for Q3 2025 at Vivos Therapeutics, down from 5013000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 17856000.0 in Q4 2022 to a low of 7412000.0 in Q4 2021.
  • A 5-year average of 3118157.89 and a median of 4043000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 197.29% in 2021, then soared 340.91% in 2022.
  • Vivos Therapeutics' Income from Continuing Operations stood at 7412000.0 in 2021, then skyrocketed by 340.91% to 17856000.0 in 2022, then plummeted by 124.09% to 4302000.0 in 2023, then surged by 34.29% to 2827000.0 in 2024, then plummeted by 91.02% to 5400000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Income from Continuing Operations are 5400000.0 (Q3 2025), 5013000.0 (Q2 2025), and 3864000.0 (Q1 2025).